Ventyx Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	33.13	32.23	25.4	8.67	0.68	0.63
Research & Development	174.08	175.77	87.74	58.48	6.37	3.55
Operating Expenses	207.21	207.99	113.14	67.15	7.05	4.18
Operating Income	-207.21	-207.99	-113.14	-67.15	-7.05	-4.18
Interest Expense / Income	0	0	0	0.1	0.36	0.15
Other Expense / Income	-14.61	-15.03	-4.71	16.5	20.77	0
Pretax Income	-192.6	-192.96	-108.43	-83.75	-28.17	-4.33
Net Income	-192.6	-192.96	-108.43	-83.75	-28.17	-4.33
Preferred Dividends	0	0	0	1.55	0	0
Net Income Common	-192.6	-192.96	-108.43	-85.3	-28.17	-4.33
Shares Outstanding (Basic)	62	59	52	13	2	2
Shares Outstanding (Diluted)	62	59	52	13	2	2
Shares Change	7.27%	11.57%	309.11%	544.96%	19.66%	-
EPS (Basic)	-3.24	-3.30	-2.07	-6.65	-14.17	-2.60
EPS (Diluted)	-3.24	-3.30	-2.07	-6.65	-14.17	-2.60
Free Cash Flow	-183.86	-167.04	-99.05	-38.91	-6.2	-2.64
Free Cash Flow Per Share	-2.97	-2.85	-1.89	-3.03	-3.12	-1.59
EBITDA	-191.39	-192.02	-107.96	-83.62	-27.82	-4.18
Depreciation & Amortization	1.22	0.94	0.47	0.03	0	0
EBIT	-192.6	-192.96	-108.43	-83.65	-27.82	-4.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).